Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival

Patrick Kellish, Daniil Shabashvili, Masmudur Rahman, Akbar Nawab, Maria V. Guijarro, Min Zhang, Chunxia Cao, Nissin Moussatche, Theresa Boyle, Scott Antonia, Mary Reinhard, Connor Hartzell, Michael Jantz, Hiren J. Mehta, Douglas McFadden, Frederic J. Kaye, Maria Zajac-Kaye

Research output: Contribution to journalArticle

Abstract

Oncolytic virotherapy has been proposed as an ablative and immunostimulatory treatment strategy for solid tumors that are resistant to immunotherapy alone; however, there is a need to optimize host immune activation using preclinical immunocompetent models in previously untested common adult tumors. We studied a modified oncolytic myxoma virus (MYXV) that shows high efficiency for tumor-specific cytotoxicity in small-cell lung cancer (SCLC), a neuroendocrine carcinoma with high mortality and modest response rates to immune checkpoint inhibitors. Using an immunocompetent SCLC mouse model, we demonstrated the safety of intrapulmonary MYXV delivery with efficient tumor-specific viral replication and cytotoxicity associated with induction of immune cell infiltration. We observed increased SCLC survival following intrapulmonary MYXV that was enhanced by combined low-dose cisplatin. We also tested intratumoral MYXV delivery and observed immune cell infiltration associated with tumor necrosis and growth inhibition in syngeneic murine allograft tumors. Freshly collected primary human SCLC tumor cells were permissive to MYXV and intratumoral delivery into patient-derived xenografts resulted in extensive tumor necrosis. We confirmed MYXV cytotoxicity in classic and variant SCLC subtypes as well as cisplatin-resistant cells. Data from 26 SCLC human patients showed negligible immune cell infiltration, supporting testing MYXV as an ablative and immune-enhancing therapy.

Original languageEnglish (US)
JournalThe Journal of clinical investigation
Volume130
DOIs
StatePublished - Apr 29 2019

Fingerprint

Oncolytic Virotherapy
Myxoma virus
Small Cell Lung Carcinoma
Survival
Neoplasms
Cisplatin
Necrosis
Oncolytic Viruses
Neuroendocrine Carcinoma
Heterografts
Immunotherapy
Allografts
Safety

Keywords

  • Lung cancer
  • Mouse models
  • Oncology
  • Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival. / Kellish, Patrick; Shabashvili, Daniil; Rahman, Masmudur; Nawab, Akbar; Guijarro, Maria V.; Zhang, Min; Cao, Chunxia; Moussatche, Nissin; Boyle, Theresa; Antonia, Scott; Reinhard, Mary; Hartzell, Connor; Jantz, Michael; Mehta, Hiren J.; McFadden, Douglas; Kaye, Frederic J.; Zajac-Kaye, Maria.

In: The Journal of clinical investigation, Vol. 130, 29.04.2019.

Research output: Contribution to journalArticle

Kellish, P, Shabashvili, D, Rahman, M, Nawab, A, Guijarro, MV, Zhang, M, Cao, C, Moussatche, N, Boyle, T, Antonia, S, Reinhard, M, Hartzell, C, Jantz, M, Mehta, HJ, McFadden, D, Kaye, FJ & Zajac-Kaye, M 2019, 'Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival', The Journal of clinical investigation, vol. 130. https://doi.org/10.1172/JCI121323
Kellish, Patrick ; Shabashvili, Daniil ; Rahman, Masmudur ; Nawab, Akbar ; Guijarro, Maria V. ; Zhang, Min ; Cao, Chunxia ; Moussatche, Nissin ; Boyle, Theresa ; Antonia, Scott ; Reinhard, Mary ; Hartzell, Connor ; Jantz, Michael ; Mehta, Hiren J. ; McFadden, Douglas ; Kaye, Frederic J. ; Zajac-Kaye, Maria. / Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival. In: The Journal of clinical investigation. 2019 ; Vol. 130.
@article{df029b64bcf047a89a1280ac30642c15,
title = "Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival",
abstract = "Oncolytic virotherapy has been proposed as an ablative and immunostimulatory treatment strategy for solid tumors that are resistant to immunotherapy alone; however, there is a need to optimize host immune activation using preclinical immunocompetent models in previously untested common adult tumors. We studied a modified oncolytic myxoma virus (MYXV) that shows high efficiency for tumor-specific cytotoxicity in small-cell lung cancer (SCLC), a neuroendocrine carcinoma with high mortality and modest response rates to immune checkpoint inhibitors. Using an immunocompetent SCLC mouse model, we demonstrated the safety of intrapulmonary MYXV delivery with efficient tumor-specific viral replication and cytotoxicity associated with induction of immune cell infiltration. We observed increased SCLC survival following intrapulmonary MYXV that was enhanced by combined low-dose cisplatin. We also tested intratumoral MYXV delivery and observed immune cell infiltration associated with tumor necrosis and growth inhibition in syngeneic murine allograft tumors. Freshly collected primary human SCLC tumor cells were permissive to MYXV and intratumoral delivery into patient-derived xenografts resulted in extensive tumor necrosis. We confirmed MYXV cytotoxicity in classic and variant SCLC subtypes as well as cisplatin-resistant cells. Data from 26 SCLC human patients showed negligible immune cell infiltration, supporting testing MYXV as an ablative and immune-enhancing therapy.",
keywords = "Lung cancer, Mouse models, Oncology, Therapeutics",
author = "Patrick Kellish and Daniil Shabashvili and Masmudur Rahman and Akbar Nawab and Guijarro, {Maria V.} and Min Zhang and Chunxia Cao and Nissin Moussatche and Theresa Boyle and Scott Antonia and Mary Reinhard and Connor Hartzell and Michael Jantz and Mehta, {Hiren J.} and Douglas McFadden and Kaye, {Frederic J.} and Maria Zajac-Kaye",
year = "2019",
month = "4",
day = "29",
doi = "10.1172/JCI121323",
language = "English (US)",
volume = "130",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",

}

TY - JOUR

T1 - Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival

AU - Kellish, Patrick

AU - Shabashvili, Daniil

AU - Rahman, Masmudur

AU - Nawab, Akbar

AU - Guijarro, Maria V.

AU - Zhang, Min

AU - Cao, Chunxia

AU - Moussatche, Nissin

AU - Boyle, Theresa

AU - Antonia, Scott

AU - Reinhard, Mary

AU - Hartzell, Connor

AU - Jantz, Michael

AU - Mehta, Hiren J.

AU - McFadden, Douglas

AU - Kaye, Frederic J.

AU - Zajac-Kaye, Maria

PY - 2019/4/29

Y1 - 2019/4/29

N2 - Oncolytic virotherapy has been proposed as an ablative and immunostimulatory treatment strategy for solid tumors that are resistant to immunotherapy alone; however, there is a need to optimize host immune activation using preclinical immunocompetent models in previously untested common adult tumors. We studied a modified oncolytic myxoma virus (MYXV) that shows high efficiency for tumor-specific cytotoxicity in small-cell lung cancer (SCLC), a neuroendocrine carcinoma with high mortality and modest response rates to immune checkpoint inhibitors. Using an immunocompetent SCLC mouse model, we demonstrated the safety of intrapulmonary MYXV delivery with efficient tumor-specific viral replication and cytotoxicity associated with induction of immune cell infiltration. We observed increased SCLC survival following intrapulmonary MYXV that was enhanced by combined low-dose cisplatin. We also tested intratumoral MYXV delivery and observed immune cell infiltration associated with tumor necrosis and growth inhibition in syngeneic murine allograft tumors. Freshly collected primary human SCLC tumor cells were permissive to MYXV and intratumoral delivery into patient-derived xenografts resulted in extensive tumor necrosis. We confirmed MYXV cytotoxicity in classic and variant SCLC subtypes as well as cisplatin-resistant cells. Data from 26 SCLC human patients showed negligible immune cell infiltration, supporting testing MYXV as an ablative and immune-enhancing therapy.

AB - Oncolytic virotherapy has been proposed as an ablative and immunostimulatory treatment strategy for solid tumors that are resistant to immunotherapy alone; however, there is a need to optimize host immune activation using preclinical immunocompetent models in previously untested common adult tumors. We studied a modified oncolytic myxoma virus (MYXV) that shows high efficiency for tumor-specific cytotoxicity in small-cell lung cancer (SCLC), a neuroendocrine carcinoma with high mortality and modest response rates to immune checkpoint inhibitors. Using an immunocompetent SCLC mouse model, we demonstrated the safety of intrapulmonary MYXV delivery with efficient tumor-specific viral replication and cytotoxicity associated with induction of immune cell infiltration. We observed increased SCLC survival following intrapulmonary MYXV that was enhanced by combined low-dose cisplatin. We also tested intratumoral MYXV delivery and observed immune cell infiltration associated with tumor necrosis and growth inhibition in syngeneic murine allograft tumors. Freshly collected primary human SCLC tumor cells were permissive to MYXV and intratumoral delivery into patient-derived xenografts resulted in extensive tumor necrosis. We confirmed MYXV cytotoxicity in classic and variant SCLC subtypes as well as cisplatin-resistant cells. Data from 26 SCLC human patients showed negligible immune cell infiltration, supporting testing MYXV as an ablative and immune-enhancing therapy.

KW - Lung cancer

KW - Mouse models

KW - Oncology

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85065407558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065407558&partnerID=8YFLogxK

U2 - 10.1172/JCI121323

DO - 10.1172/JCI121323

M3 - Article

VL - 130

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

ER -